Implementing the Risk Stratification and Clinical Management of Breast Cancer Families Using Polygenic Risk Score Evaluation: A Pilot Study

Overview

Journal J Pers Med

Date 2024 Oct 25

PMID 39452541

Authors

Barbara Rizzacasa

Vanessa Nicoli

Chantal Tancredi

Chiara Conte

Leila B Salehi

Miriam Lucia Carriero

Giuliana Longo

Vincenzo Cirigliano

Luis Izquierdo Lopez

Bibiana Palao

Ilaria Portarena

Oreste Claudio Buonomo

Giuseppe Novelli

Michela Biancolella

Affiliations

Soon will be listed here.

Abstract

Background: The identification of women at high risk of breast cancer (BC) is crucial for personalized screening strategies. Pathogenic and likely pathogenic variants (PVs/LPVs) in susceptibility risk genes explain part of the individual risk. Moreover, a polygenic background, summarized as a polygenic risk score (PRS), contributes to the risk of BC and may modify the individual risk in carrier and non-carrier members of BC families.

Methods: We performed a retrospective pilot study evaluating PRS in women from a subset of high- ( and and moderate-risk ( and ) BC families. We included PVs/LPVs carriers and non-carriers and evaluated a PRS based on 577,113 BC-associated variants. Using BOADICEA, we calculated the adjusted lifetime BC risk.

Results: Our data showed that in carriers, PVs have a major role in stratifying the lifetime risk, while PRS improves risk estimation in non-carriers of these families. A different scenario may be observed in and families where PRS combined with PV/LPV carrier status gives a more informative lifetime risk.

Conclusions: This study showed that in BC families, the PRS might help to quantify the weight of the genetic familial background, improving the individual risk stratification and contributing to personalized clinical management for carrier and non-carrier women.

Citing Articles

Stability of Blood DNA Methylation Across Two Timepoints in Three Cohorts.

Danielewski M, Walkowiak J, Wielgus K, Nowak J Biomedicines. 2024; 12(11).

PMID: 39595122 PMC: 11592101. DOI: 10.3390/biomedicines12112557.

References

Carver T, Hartley S, Lee A, Cunningham A, Archer S, de Villiers C . CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. Cancer Epidemiol Biomarkers Prev. 2020; 30(3):469-473. PMC: 7611188. DOI: 10.1158/1055-9965.EPI-20-1319. View

Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M . ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006; 38(8):873-5. DOI: 10.1038/ng1837. View

Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View

Sun J, Chu F, Pan J, Zhang Y, Yao L, Chen J . BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for Carriers. J Clin Oncol. 2022; 41(5):991-999. DOI: 10.1200/JCO.22.00833. View

Lakeman I, Rodriguez-Girondo M, Lee A, Celosse N, Braspenning M, van Engelen K . Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases. J Med Genet. 2022; 60(4):327-336. DOI: 10.1136/jmg-2022-108502. View

Mukama T, Fallah M, Brenner H, Xu X, Sundquist K, Sundquist J . Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study. BMC Med. 2020; 18(1):295. PMC: 7643418. DOI: 10.1186/s12916-020-01772-x. View

Burton H, Chowdhury S, Dent T, Hall A, Pashayan N, Pharoah P . Public health implications from COGS and potential for risk stratification and screening. Nat Genet. 2013; 45(4):349-51. DOI: 10.1038/ng.2582. View

Stucci L, Interno V, Tucci M, Perrone M, Mannavola F, Palmirotta R . The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes (Basel). 2021; 12(5). PMC: 8152746. DOI: 10.3390/genes12050727. View

Mars N, Widen E, Kerminen S, Meretoja T, Pirinen M, Briotta Parolo P . The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nat Commun. 2020; 11(1):6383. PMC: 7736877. DOI: 10.1038/s41467-020-19966-5. View

10.

Yoshida R . Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2020; 28(6):1167-1180. PMC: 8514387. DOI: 10.1007/s12282-020-01148-2. View

11.

Ochaney P, Patel K, Haq F, Reese R, Igel S . The Importance of Risk-Reducing Prophylactic Mastectomy in Breast Cancer (BRCA) Carriers: A Case Report. Cureus. 2019; 11(8):e5311. PMC: 6773448. DOI: 10.7759/cureus.5311. View

12.

Busby G, Kulm S, Bolli A, Kintzle J, Di Domenico P, Botta G . Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments. Nat Commun. 2023; 14(1):7105. PMC: 10625612. DOI: 10.1038/s41467-023-42897-w. View

13.

Lakeman I, Hilbers F, Rodriguez-Girondo M, Lee A, Vreeswijk M, Hollestelle A . Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non- breast cancer families. J Med Genet. 2019; 56(9):581-589. DOI: 10.1136/jmedgenet-2019-106072. View

14.

Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S . Enhancing the BOADICEA cancer risk prediction model to incorporate new data on , , updates to tumour pathology and cancer incidence. J Med Genet. 2022; 59(12):1206-1218. PMC: 9691826. DOI: 10.1136/jmedgenet-2022-108471. View

15.

Milne R, Kuchenbaecker K, Michailidou K, Beesley J, Kar S, Lindstrom S . Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017; 49(12):1767-1778. PMC: 5808456. DOI: 10.1038/ng.3785. View

16.

Lee A, Mavaddat N, Wilcox A, Cunningham A, Carver T, Hartley S . BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019; 21(8):1708-1718. PMC: 6687499. DOI: 10.1038/s41436-018-0406-9. View

17.

Gao C, Polley E, Hart S, Huang H, Hu C, Gnanaolivu R . Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. J Clin Oncol. 2021; 39(23):2564-2573. PMC: 8330969. DOI: 10.1200/JCO.20.01992. View

18.

Angeli D, Salvi S, Tedaldi G . Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?. Int J Mol Sci. 2020; 21(3). PMC: 7038038. DOI: 10.3390/ijms21031128. View

19.

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A . Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2018; 104(1):21-34. PMC: 6323553. DOI: 10.1016/j.ajhg.2018.11.002. View

20.

Pashayan N, Duffy S, Chowdhury S, Dent T, Burton H, Neal D . Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer. 2011; 104(10):1656-63. PMC: 3093360. DOI: 10.1038/bjc.2011.118. View